CTRI/2024/03/063840招募中4 期
A Single Center, Randomized, Open-Label, Prospective, Parallel Group Study to Evaluate antifungal and biofilm inhibition activity of formulation containing Lactoferrin cream + Luliconazole cream against Luliconazole Cream in the Treatment of Patients with cutaneous Candidiasis and Dermatophytosis - Nill
Frimline Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients will be included in the study if they meet all the following criteria:
- •1.Male or female patients aged between 18 to 65 years (both inclusive) with a clinical diagnosis of mycologically proven cutaneous candidiasis or dermatophytosis (Tinea/ Ringworm). Cutaneous candidiasis includes below-
- •A. Candidial folliculitis
- •B. Candidal intertrigo
- •C. Candidal paronychia
- •D. Perianal candidiasis
- •E. Candidid
- •F. Chronic mucocutaneous candidiasis
- •G. Congenital cutaneous candidiasis
- •H. Erosio interdigitalis blastomycetica
- •I. Candidial onychomycosis
- •Dermatophytosis includes
- •A. Tinea barbae
- •B. Tinea capitis
- •C. Tinea corporis
- •D. Tinea cruris
- •E. Tinea pedis
- •2. Patients with localized superficial fungal infection confirmed by the presence of fungal hyphae in KOH (potassium hydroxide) preparation of skin scrapings from over the lesion at screening visit
- •3. Patients agree not to use ƒany other topical product on the affected area during the entire course of study except for non-medicated, investigator-approved cleanser, and sunscreen. Patients should continue to use these investigator-approved products for the duration of the study and should avoid any changes in these consumer products.
- •4. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening/ baseline visit.
- •5. Patients with the ability to understand and provide a written informed consent form before the screening.
- •6. Patients willing to comply with the protocol requirements throughout the study.
排除标准
- •Patients are excluded from the study if any of the following criteria apply
- •1. Patients with known or suspected hypersensitivity to quinolone antibacterial agents or azoles for example Ketoconazole.
- •2. Patients with the presence of any skin condition that would interfere with the diagnosis or assessment of cutaneous candidiasis.
- •3. Patients receiving treatment with the following products
- •a. Systemic antifungals for the treatment of cutaneous candidiasis in the 30 days before the baseline visit.
- •b. Any medication or procedure that, in the opinion of the investigator, would put the Patient at unacceptable risk for participation in the study or may interfere with evaluations in the study.
- •4. Patients with uncontrolled hypertension with sitting systolic BP 160 mmHg and or diastolic BP100 mmHg at screening.
- •5. Females who are pregnant or lactating or planning to become pregnant during the study period.
- •6. Patients with a history of experiencing significant burning or stinging when applying any topical treatment.
- •7. Patients with a serious and or chronic medical conditions.
- •8. Patients with a history of substance abuse or dependence that in the opinion of the Investigator considered interfering with the patients participation in the study.
- •9. Patients with concurrent participation in another clinical trial or any investigational therapy within 90 days before signing informed consent.
研究者
相似试验
招募中
不适用
Study to compare efficacy and safety of Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy of Hepatitis B virus Surface Antigen in PatientsDiseases of the digestive systemKCT0001395Seoul National University Hospital150
进行中（未招募）
不适用
Continuation of cholic acid treatment for people with bile acid disorders who have previously taken part in clinical trials of cholic acid capsules.Patients with inborn errors of bile acid synthesis and metabolismMedDRA version: 14.0Level: PTClassification code 10070882Term: Inborn error in primary bile acid synthesisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004528-36-Outside-EU/EEAAsklepion Pharmaceuticals, LLC30
进行中（未招募）
1 期
A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with high residual level of voluntary functioEUCTR2007-007165-20-DKShire Pharmaceuticals Ireland Limited6
进行中（未招募）
不适用
A single center, open-label, non-randomized, uncontrolled, multiple-dose, dose escalation study of the safety, pharmacokinetics and efficacy of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patients with late infantile metachromatic leukodystrophy (MLD)ate infantile metachromatic leukodystrophy (MLD)MedDRA version: 9.1Level: LLTClassification code 10024381Term: LeukodystrophyEUCTR2006-005341-11-DKShire Pharmaceuticals Ireland Limited12
进行中（未招募）
不适用
A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and long-term safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patients with late infantile metachromatic leukodystrophyEUCTR2007-006345-40-DKShire Pharmaceutical Ireland Limited